Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

NCT05302037 | Recruiting Phase 1 DMC

• 1 other identifier: CTM-N2D-102
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient. Then in the lab, an artificial protein - a Chimeric Antigen Receptor (CAR), is grafted on the surface of immune cells. The modified cells, which are readministered to the patient, have enhanced abilities to target and destroy cancers than unmodified immune cells. Currently approved CAR-T can only be used autologously. i.e. the patient will receive CAR-T treatment made from their own cells. This is because current CAR-T treatment uses αβ T cells - a type of immune cell which are largely non-transferable between individual human beings due to the high risk of Graft-versus-Host Disease. However, autologous CAR-T comes with many limitations. A lengthy, manufacturing process follows after the patient donates their own blood, accompanied by a high risk of manufacturing failure, which can be attributed to the cell quality from cancer patients undergoing stressful anti-cancer therapy. CytoMed Therapeutics pioneers a new CAR-T treatment (CTM-N2D) which may confer some benefit over current CAR-T treatment. CTM-N2D uses a subtype of immune cell -- γδ T cell. Secondly, the CAR on CTM-N2D targets a surface antigen called NKG2DL which are commonly present in many cancer. These two features may confer a safer product profile, of better quality and may be efficacious in cancers where previous CAR-T treatments has not. The phase I clinical trial of CTM-N2D will be conducted at the National University Hospital, Singapore. The objective of this clinical trial is to determine the optimal dose of CTM-N2D, and to investigate its safety and tolerability. The subjects of the clinical trial will also be investigated for their tumour response to CTM-N2D. CTM-N2D has undergone preclinical studies. Relevant data from other clinical trials are also used to infer the expected outcome, and strategies of management of this clinical trial. The institution's ethical review board must give its approval before the study may begin. An independent Data Safety Monitoring Board monitors the safety aspect of this trial.

Conditions

Cancer; Malignancy; Refractory Cancer; Relapsed Cancer

Keywords

cancer; malignancy; solid cancer; solid tumours; haematological cancer; haematological malignancy; refractory cancer; relapsed cancer; CAR-T; cell therapy; gamma delta

Outcome Measures

Primary Outcomes (2)

• To determine a dose regimen and schedule of CTM-N2D at which no more than one patient out of up to six patients at the same dose level experience a CTM-N2D-related DLT

  Cohort 1: Three patients will be treated with four escalating doses of CTM-N2D to determine an optimal dose based on the incidence of DLT. DLT is defined as an unexpected grade 3 or 4 non-hematologic toxicity that is probably related to CTMN2D infusion and experienced within 8 weeks immediately after the start of study treatment. Treatments with maintenance doses of CTM-N2D will not be considered in determining DLT.

  Within 8 weeks immediately after the start of study treatment

• Number of Participants With Treatment-Related Adverse Events as assessed by NCI CTCAE v5.0

  Cohort 2: Six patients will be treated with four infusions of CTM-N2D at the optimal dose determined in Cohort 1.

  24 months after the start of study treatment

Secondary Outcomes (4)

• Maximum objective response rate according to RECIST v1.1

  24 months after the start of study treatment

• Progression-free survival (PFS)

  Up to 48 months after the last patient was initiated for study treatment

• Overall survival (OS)

  Up to 48 months after the last patient was initiated for study treatment

• Duration of response in patients with objective response up to M24 after the start of study treatment (i.e., C1:1D1)

  Up to 48 months after the last patient was initiated for study treatment

Other Outcomes (2)

• Detection and quantification of lymphocyte subsets including γδ T cell subset in blood

  24 months after the start of study treatment

• Detection and quantification of serum cytokines

  24 months after the start of study treatment

Study Arms (2)

Dose-Escalation Arm

EXPERIMENTAL

Four infusions of CTM-N2D at escalating doses: 1x10\^7, 1x10\^8, 3x10\^8 or 1x10\^9 per infusion at an interval of one infusion every 7 days.

Biological: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

Optimal Dose Arm

EXPERIMENTAL

Four infusions of CTM-N2D at the optimal dose (expected to be 1x10\^9) at an interval of one infusion every 7 days.

Biological: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

Interventions

Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) BIOLOGICAL

In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.

Dose-Escalation Arm; Optimal Dose Arm

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At least 21 years of age
• Provision of signed and dated, written informed consent prior to any study specific procedures, sampling, and analyses (if applicable, the written informed consent may include access to all archival tumour tissue, e.g., diagnostic and/or most recent samples for correlative study)
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and an estimated life expectancy of greater than 12 weeks
• Females of reproductive age group must be on effective contraception (if sexually active), must not be breast feeding and must have a negative pregnancy test prior to the start of lymphodepletion.
• For the duration of the study and for 1 week after the last study drug administration, sexually active male patients must be willing to use barrier contraception (i.e., condoms) with all sexual partners. Where the sexual partner is a 'woman of child-bearing potential' who is not using effective contraception, the male patients must use a condom (with spermicide) during the study and for 6 months after the last dose of a study drug.
• Adequate hepatic, renal and lung function as demonstrated by any of the following laboratory values:
• AST or ALT ≤ 3 x ULN
• Total bilirubin ≤ 1.5 x ULN
• Glomerular filtration rate (GFR) \> 50 mL/min, as assessed using the Cockroft-Gault formula or 24 h urine creatinine collection
• SpO2 on room air \> 94%
• Adequate bone marrow reserve as demonstrated by any of the following laboratory values:
• Absolute neutrophil count (ANC) ≥ 1.0x10\^9/L
• Platelet count ≥ 75 x 10\^9/L
• Haemoglobin ≥ 9.0 g/dL
• Patients must have a metastatic cancer resistant to or deemed unsuitable for at least two standard lines of cancer therapy regimens, as part of their management of recurrent/persistent disease.

You may not qualify if:

• With the exception of alopecia, any unresolved toxicities from prior therapy ≥ the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 2
• Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to the start of lymphodepletion
• As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, active bleeding diatheses, renal transplant, or active infection including any patient known to have human immunodeficiency virus (HIV) or hepatitis virus. Screening for chronic conditions is not required.
• All HBsAg-positive patients (For HBsAg-negative, but anti-HBc total-positive patients, HBV viral load will be further tested. If HBV viral load is negative, patients may be included.)
• Active or prior documented autoimmune or inflammatory disorders including inflammatory bowel disease (e.g., colitis or Crohn's disease), diverticulitis (with the exception of diverticulosis), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc). The following are exceptions to this criterion:
• Subjects with vitiligo or alopecia
• Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
• Any chronic skin condition that does not require systemic therapy
• Subjects without active disease in the last 5 years may be included but only after consultation with the medical monitor
• Subjects with celiac disease controlled by diet alone
• For other autoimmune or inflammatory conditions not specifically mentioned, discuss on case-by-case basis with investigator and medical monitor
• Concurrent severe and/or uncontrolled medical condition (e.g., severe COPD, severe Parkinson's disease, active inflammatory bowel disease) or psychiatric condition (screening for chronic disease is not required)
• Female patients who are breast-feeding or patients of reproductive potential who are not employing an effective method of contraception
• Receiving, or having received during the four weeks prior the start of lymphodepletion, any investigational product
• Treatment with any investigational biological product (e.g., immune check point blockers, antibodies, nanoparticles, experimental) during the four weeks prior the start of lymphodepletion

Sponsors & Collaborators

• CytoMed Therapeutics Pte Ltd: lead
• National University Hospital, Singapore: collaborator

Study Sites (1)

National University Hospital

Singapore, Singapore

RECRUITING

Related Publications (6)

• Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S. Exploiting natural killer group 2D receptors for CAR T-cell therapy. Future Oncol. 2017 Aug;13(18):1593-1605. doi: 10.2217/fon-2017-0102. Epub 2017 Jun 14.

  PMID: 28613086 BACKGROUND

• Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg. 2010 May;37(5):1191-7. doi: 10.1016/j.ejcts.2009.11.051.

  PMID: 20137969 BACKGROUND

• Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K. Intraperitoneal injection of in vitro expanded Vgamma9Vdelta2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med. 2014 Apr;3(2):362-75. doi: 10.1002/cam4.196. Epub 2014 Feb 7.

  PMID: 24515916 BACKGROUND

• Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, Kunzmann V. Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells. J Transl Med. 2014 Feb 15;12:45. doi: 10.1186/1479-5876-12-45.

  PMID: 24528541 BACKGROUND

• Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595.

  PMID: 31187535 BACKGROUND

• Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.

  PMID: 28925994 BACKGROUND

MeSH Terms

Conditions

Neoplasms; Recurrence; Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Anand D Jeyasekharan, Dr

  National University Health System (NUHS)

  PRINCIPAL INVESTIGATOR

• Jieming Zeng, Dr

  CytoMed Therapeutics Pte Ltd

  STUDY DIRECTOR

Central Study Contacts

Anand D Jeyasekharan, Dr

CONTACT

+65 6908 2222; anand_jeyasekharan@nuhs.edu.sg

Jieming Zeng, Dr

CONTACT

+65 8428 8970; jiemingzeng@cytomed.sg

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 20, 2022
• First Posted: March 31, 2022
• Study Start: November 19, 2024
• Primary Completion: November 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: November 22, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

SG (1)